je.st
news
Short Regeneron: Further Downside Ahead For This Bloated Large-Cap...
2016-03-07 18:44:11| Biotech - Topix.net
Regeneron reported disappointing full-year 2015 results in early February, and once booming sales of EYLEA are starting to finally exhibit some sluggishness. The company's heavily-anticipated PCSK9 drug, Praluent, launched in mid-2015, but has yet to exhibit sales that were expected from the potential billion-dollar rock star.
Tags: short
ahead
downside
bloated
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||